|
Hypercholesterolemia, Familial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation.
|
24632281 |
2014 |
|
Hypercholesterolemia, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lipoprotein(a) [Lp(a)] increases CAD in FH, although the independence of this association relative to other CAD risk factors remains unclear.
|
26340131 |
2015 |
|
Hypercholesterolemia, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lipoprotein(a) in Familial Hypercholesterolemia With Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gain-of-Function Mutations.
|
26632531 |
2016 |
|
Hypercholesterolemia, Familial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Lipoprotein(a) level associates with coronary artery disease rather than carotid lesions in patients with familial hypercholesterolemia.
|
29603377 |
2018 |
|
Hypercholesterolemia, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lipoprotein(a) concentration is associated with plasma arachidonic acid in subjects with familial hypercholesterolaemia.
|
31262370 |
2019 |
|
Hypercholesterolemia, Familial
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Apolipoprotein(a) polymorphism predicts the increase of Lp(a) by pravastatin in patients with familial hypercholesterolaemia treated with bile acid sequestration.
|
8500516 |
1993 |
|
Hypercholesterolemia, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Apolipoprotein (a) [apo(a)] phenotype was determined in 112 of FH and non-FH subjects.
|
8548413 |
1996 |
|
Hypercholesterolemia, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
A modified algorithm with lipoprotein(a) added for diagnosis of familial hypercholesterolemia.
|
31436336 |
2019 |
|
Hypercholesterolemia, Familial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
An investigation of the influence of selected factors on the clinical expression of the FH Afrikaner-1 mutation in this family indicated that it was especially the elevated apolipoprotein (a) levels, in addition to low levels of high density lipoprotein cholesterol and raised triglyceride and apolipoprotein B levels, that were associated with a greater risk of developing CHD.
|
8370148 |
1993 |
|
Hypercholesterolemia, Familial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Baseline and on-statin treatment lipoprotein(a) levels for predicting cardiovascular events in patients with familial hypercholesterolemia.
|
31683090 |
2019 |
|
Hypercholesterolemia, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Depicting new pharmacological strategies for familial hypercholesterolaemia involving lipoprotein (a).
|
29029165 |
2017 |
|
Hypercholesterolemia, Familial
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Detection of the Pro664-Leu mutation in the low-density lipoprotein receptor and its relation to lipoprotein(a) levels in patients with familial hypercholesterolemia of Dutch ancestry from The Netherlands and Canada.
|
1493640 |
1992 |
|
Hypercholesterolemia, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Determination of apolipoprotein(a) (apo(a)) phenotype and lipoprotein(a) (Lp(a)) concentration in plasma revealed that in many instances, involving individuals with various apo(a) phenotypes, there was no difference in plasma Lp(a) concentration between an FH heterozygote and an unaffected sibling with the same apo(a) phenotype.
|
1830890 |
1991 |
|
Hypercholesterolemia, Familial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Diverse effect of ethnicity on plasma lipoprotein[a] levels in heterozygote patients with familial hypercholesterolemia.
|
1836489 |
1991 |
|
Hypercholesterolemia, Familial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Elevated lipoprotein(a) levels contribute to the occurrence and severity of early-onset coronary disease and add to the already enhanced risk in patients with familial hypercholesterolaemia.
|
12889664 |
2003 |
|
Hypercholesterolemia, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Elevated lipoprotein(a) and familial hypercholesterolemia in the coronary care unit: Between Scylla and Charybdis.
|
29480541 |
2018 |
|
Hypercholesterolemia, Familial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Elevated levels of lipoprotein (a) in children with familial hypercholesterolemia.
|
8197753 |
1994 |
|
Hypercholesterolemia, Familial
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Familial hypercholesterolemia (FH) and elevated lipoprotein(a) [Lp(a)] are inherited disorders associated with premature atherosclerotic cardiovascular disease (ASCVD).
|
30846097 |
2019 |
|
Hypercholesterolemia, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genetic traits for familial hypercholesterolemia and high lipoprotein(a) concentrations apparently co-exist and are associated with a higher ASVCD risk than each alone.
|
31393421 |
2019 |
|
Hypercholesterolemia, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, when adjusting LDL cholesterol for lipoprotein(a) cholesterol content the corresponding values were 24 mg/dL for individuals unlikely to have familial hypercholesterolaemia, 22 mg/dL for those with possible familial hypercholesterolaemia, and 21 mg/dL for those with probable or definite familial hypercholesterolaemia (ptrend=0·46).
|
27185354 |
2016 |
|
Hypercholesterolemia, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Increasing attention has come upon the genetic disorders of familial hypercholesterolemia and elevated lipoprotein(a).
|
28429242 |
2017 |
|
Hypercholesterolemia, Familial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Low-density lipoprotein cholesterol (LDL-C) level and lipoprotein(a) [Lp(a)] ≥ 50 mg/dL predict atherosclerotic cardiovascular disease (ASCVD) risk in adults with familial hypercholesterolemia (FH), but their role for children with FH is less clear.
|
30150142 |
2019 |
|
Hypercholesterolemia, Familial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemia.
|
27594539 |
2016 |
|
Hypercholesterolemia, Familial
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Phase 2 and 3 clinical trials in patients with moderate and severe hypercholesterolemia (including FH) show that this approach is safe and highly efficacious to lower LDL-C and lipoprotein(a).
|
25248569 |
2014 |
|
Hypercholesterolemia, Familial
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recent literature involving CNVs and dyslipidemias has focused mainly on rare CNVs causing familial hypercholesterolemia, and a common CNV polymorphism as the major determinant of lipoprotein(a) plasma concentrations.
|
29303791 |
2018 |